BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $16.56.

A number of research firms have recently commented on BCRX. Wedbush assumed coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 price target on the stock. Royal Bank Of Canada restated an "outperform" rating and issued a $13.00 target price (up from $11.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. Barclays lifted their price target on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an "equal weight" rating in a research note on Wednesday, May 7th. HC Wainwright reissued a "buy" rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. Finally, JPMorgan Chase & Co. raised their price objective on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a report on Tuesday, May 6th.

BioCryst Pharmaceuticals Trading Down 1.9%

Shares of BCRX stock traded down $0.19 during trading hours on Friday, reaching $9.74. 3,633,310 shares of the stock were exchanged, compared to its average volume of 3,016,718. The firm has a market capitalization of $2.04 billion, a price-to-earnings ratio of -37.46, a price-to-earnings-growth ratio of 2.24 and a beta of 1.11. BioCryst Pharmaceuticals has a 12-month low of $6.00 and a 12-month high of $11.31. The company's 50-day moving average price is $9.82 and its 200-day moving average price is $8.52.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Rhumbline Advisers increased its holdings in shares of BioCryst Pharmaceuticals by 1.8% in the 4th quarter. Rhumbline Advisers now owns 309,132 shares of the biotechnology company's stock valued at $2,325,000 after acquiring an additional 5,615 shares during the period. Venturi Wealth Management LLC bought a new stake in BioCryst Pharmaceuticals during the fourth quarter valued at about $46,000. Ieq Capital LLC bought a new stake in BioCryst Pharmaceuticals during the fourth quarter valued at about $221,000. Los Angeles Capital Management LLC grew its stake in BioCryst Pharmaceuticals by 16.9% in the fourth quarter. Los Angeles Capital Management LLC now owns 101,188 shares of the biotechnology company's stock valued at $761,000 after purchasing an additional 14,655 shares during the last quarter. Finally, Proficio Capital Partners LLC bought a new position in BioCryst Pharmaceuticals in the fourth quarter worth about $192,000. Institutional investors own 85.88% of the company's stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.